GlassScriptPhysician profile
Alexis Moses
NPI 1720445919
$7,787.24
in general payments reported to CMS, 2019-2025
24 companies · $1,555 in 2025
The $1,555 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,083 · 2022: $1,838 · 2023: $1,627 · 2024: $1,684 · 2025: $1,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,790 · Education: $76.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,789.63 |
| Education | $76.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,654.56 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $944.26 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $928.81 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $792.45 | 2021-2025 | Ilumya |
| Ucb, INC. | $631.48 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $452.52 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $430.56 | 2021-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $341.67 | 2021-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $335.06 | 2021-2024 | |
| Incyte Corporation | $284.91 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $171.70 | 2022-2023 | Sotyktu |
| Dermavant Sciences, INC. | $120.49 | 2023-2024 | Vtama |
| Genentech USA, INC. | $111.64 | 2021-2022 | |
| Almirall LLC | $110.61 | 2023-2025 | Seysara |
| Organogenesis INC. | $93.00 | 2022-2024 | Affinity, Novachor |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $86.84 | 2021-2023 | |
| Genzyme Corporation | $80.86 | 2022 | |
| Boston Scientific Corporation | $58.87 | 2024 | Wavewriter Alpha Prime 16 |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.31 | 2021-2022 | |
| Convatec INC. | $32.18 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.12 | 2024 | Spevigo |
| Alnylam Pharmaceuticals INC. | $22.71 | 2024 | Givlaari |
| Organon LLC | $20.53 | 2025 | |
| Verrica Pharmaceuticals INC. | $13.10 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Moses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.